HC Wainwright Begins Coverage on Neumora Therapeutics (NASDAQ:NMRA)

HC Wainwright initiated coverage on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $30.00 price objective on the stock. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2024 earnings at ($0.33) EPS, Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.37) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at $0.40 EPS.

NMRA has been the topic of a number of other reports. Needham & Company LLC reaffirmed a buy rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Thursday, September 12th. Royal Bank of Canada reaffirmed an outperform rating and issued a $29.00 price target on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Finally, Mizuho started coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They set an outperform rating and a $20.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $22.90.

Neumora Therapeutics Trading Down 3.0 %

Shares of NMRA stock opened at $13.55 on Tuesday. The company’s fifty day moving average price is $12.00 and its two-hundred day moving average price is $11.20. Neumora Therapeutics has a 12 month low of $8.33 and a 12 month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.37). On average, analysts anticipate that Neumora Therapeutics will post -1.51 EPS for the current year.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the sale, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. The disclosure for this sale can be found here. Insiders sold a total of 90,926 shares of company stock worth $1,067,758 over the last 90 days. Insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors have recently modified their holdings of the company. Quarry LP acquired a new position in shares of Neumora Therapeutics during the second quarter worth approximately $98,000. The Manufacturers Life Insurance Company increased its position in Neumora Therapeutics by 79.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company’s stock valued at $1,099,000 after acquiring an additional 49,527 shares during the period. Marshall Wace LLP acquired a new position in Neumora Therapeutics during the 2nd quarter worth $1,323,000. Callan Capital LLC grew its stake in shares of Neumora Therapeutics by 222.6% in the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after purchasing an additional 456,207 shares in the last quarter. Finally, SkyOak Wealth LLC bought a new position in shares of Neumora Therapeutics in the second quarter worth $147,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.